A chromosome region can be present in two copies yet lack the gene activity required for normal development. Genomic imprinting explains this apparent contradiction: at selected loci, expression depends on whether a copy came from the egg or sperm. For clinicians, this creates a diagnostic question that sequence analysis or copy-number assessment alone may leave unanswered.
Parental origin is biological information
Most genes do not follow an imprinting pattern. At imprinted loci, however, chemical marks help regulate expression according to parental origin. DNA methylation is one component of this regulation. These marks affect gene activity without necessarily altering the underlying sequence. Imprinted genes often occur in clusters, including regions on chromosomes 11 and 15. MedlinePlus Genetics explains imprinting and its relationship to inheritance.
Uniparental disomy, or UPD, means that both copies of a chromosome or chromosome segment derive from one parent. UPD often has no clinical consequence, but at an imprinted region it can remove the normally active parental contribution. A normal chromosome count therefore does not establish normal parental inheritance or normal gene expression.
Chromosome 15 illustrates two different consequences
Loss of paternal expression: Prader-Willi syndrome
Prader-Willi syndrome results from loss of expression of normally active paternal genes in the relevant chromosome 15 region. Mechanisms include a paternal deletion, maternal UPD, and an imprinting defect that inappropriately silences the paternal contribution. Thus, the same clinical syndrome can arise through different molecular routes.
The phenotype also changes with age. Neonatal hypotonia, feeding difficulty and poor growth can precede the marked hunger and weight-related problems seen later. Waiting for the later phenotype can delay recognition. Several genes contribute to the disorder; the precise relationship between individual genes and all clinical features remains incompletely understood. The MedlinePlus Prader-Willi syndrome overview describes these mechanisms and clinical features.
Loss of maternal UBE3A function: Angelman syndrome
Angelman syndrome involves loss of maternal UBE3A function in the brain, where the paternal copy is normally largely inactive in neurons. Mechanisms include a maternal deletion, paternal UPD, an imprinting defect, or a pathogenic variant affecting the maternal UBE3A copy.
Developmental impairment, severe speech limitation, movement or balance difficulties, and seizures can prompt investigation. These findings are not individually diagnostic. The shared chromosome region should not obscure the different gene-expression consequences of the two syndromes. MedlinePlus describes Angelman syndrome and its tissue-specific UBE3A expression.
Match the assay to the mechanism
Testing should distinguish three questions: is the regional imprint abnormal, is DNA missing, and what caused the abnormal parental contribution? A single assay may answer only some of them.
- Methylation analysis assesses the parent-specific imprint at the tested locus.
- Copy-number analysis can identify a deletion but does not by itself establish every imprinting mechanism.
- Parental-origin studies and targeted sequence testing help resolve mechanisms that remain unexplained.
For suspected Prader-Willi syndrome, an abnormal methylation result can establish the diagnosis while leaving deletion, UPD and imprinting defect to be distinguished. For Angelman syndrome, methylation testing detects several major mechanisms but does not detect all pathogenic UBE3A sequence variants. Consequently, a normal methylation result has different implications in the two conditions. The EMQN/ACGS molecular testing guidelines explain these assay-specific pathways and limitations.
The practical implication is to review the laboratory’s actual methods and reported scope. An earlier exome result, microarray result or generic statement that “genetic testing was normal” cannot substitute for confirming whether the relevant imprinting mechanism was assessed.
Resolve the mechanism before assigning recurrence risk
Most cases of both syndromes arise without an affected family history. Nevertheless, some underlying changes can be inherited. A syndrome label alone therefore cannot support a precise recurrence estimate. Counselling should incorporate the molecular mechanism, relevant parental investigations and any residual uncertainty. The inheritance sections of the Prader-Willi and Angelman summaries describe this distinction.
Keep mechanistic research separate from clinical conclusions
Established diagnostic testing uses validated measurements of methylation, dosage, sequence or inheritance. Research seeks deeper explanations of how altered expression produces particular features. For example, work implicating the SNORD116 cluster in Prader-Willi syndrome does not yet explain every manifestation. Mechanistic plausibility alone cannot establish treatment benefit or predict an individual’s course. A molecular diagnosis can clarify the disorder and inform counselling while substantial uncertainty about severity and future outcomes remains.